secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2023-07-24T23:59:59+00:00
Accession:  0001193125-23-191859
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verrica FDA approves YCANTH for molluscum; secures up to $125M debt financing
-----------------------------------------------------------------------------

- YCANTH (cantharidin 0.7%) topical solution approved for molluscum contagiosum in patients 2+ years; first FDA-approved treatment for the indication.
- Phase 3 CAMP-1: 46% complete clearance vs 18% placebo (p<0.0001); CAMP-2: 54% vs 13% (p<0.0001).
- Non-binding term sheet for up to $125M debt facility; $50M available immediately at close, expected by end of week.
- Debt is 5-year term loan bearing SOFR + 8% (4% floor); warrant for $3.1M common stock at 10-day VWAP.
- Verrica plans commercial launch by September 2023; cash runway extended into Q1 2025 with $60M on hand plus $50M upfront.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312523191859/0001193125-23-191859-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312523191859/d542791d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-191859

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer